Alliance Pharma Plc Downgraded by Investec to Sell (APH)
Alliance Pharma Plc (LON:APH) was downgraded by stock analysts at Investec to a “sell” rating in a report issued on Tuesday, Stock Ratings Network reports. They currently have a GBX 30 ($0.49) price objective on the stock, down from their previous price objective of GBX 33 ($0.54). Investec’s price target would suggest a potential downside of 11.89% from the company’s current price.
Shares of Alliance Pharma Plc (LON:APH) traded down 4.08% during mid-day trading on Tuesday, hitting GBX 34.05. 383,053 shares of the company’s stock traded hands. Alliance Pharma Plc has a 52-week low of GBX 31.45 and a 52-week high of GBX 40.50. The stock’s 50-day moving average is GBX 37.60 and its 200-day moving average is GBX 35.52.
A number of other analysts have also recently weighed in on APH. Analysts at FinnCap reiterated a “hold” rating on shares of Alliance Pharma Plc in a research note to investors on Tuesday. They now have a GBX 38.50 ($0.63) price target on the stock. Separately, analysts at Numis Securities Ltd reiterated an “add” rating on shares of Alliance Pharma Plc in a research note to investors on Wednesday, December 18th. They now have a GBX 41 ($0.68) price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The company presently has an average rating of “Hold” and an average price target of GBX 36.14 ($0.60).
Alliance Pharma plc is engaged in the acquisition, marketing and distribution of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.